Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.10.0.1
Consolidated Statements of Operations - USD ($)
12 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Research and development    
Compensation and benefits $ 5,603,671 $ 7,001,151
Consultants and outside costs 651,155 762,670
Material manufacturing costs 1,162,368 2,596,809
Facilities and other costs 1,962,315 1,734,104
Total research and development 17,279,548 12,094,734
General and administrative    
Compensation and benefits 6,683,490 5,569,426
Professional fees 762,389 1,100,480
Investor relations 317,052 327,556
General and administrative 1,337,319 1,231,852
Impairment of long-lived assets 1,691,391 0
Loss on sale of fixed assets 663,017 0
Total General and Administrative 11,454,658 8,229,314
Total operating expenses 28,734,206 20,324,048
Loss from operations (28,734,206) (20,324,048)
Other (expense) income    
Interest income 1,000 0
Rent income 136,127 37,144
Interest expense (689,188) (1,595)
Loss on extinguishment of debt (602,193) 0
Derivative gains 26,684 11,367
Total other (expense) income (1,127,570) 46,916
Net loss (29,861,776) (20,277,132)
Warrant modification deemed dividend 0 (3,406,932)
Net loss attributable to common stock $ (29,861,776) $ (23,684,064)
Net loss per common share - basic and diluted $ (0.53) $ (0.57)
Weighted average number of common shares outstanding - basic and diluted 55,654,934 41,296,741
Clinical trial costs    
Research and development    
Cost of Goods and Services Sold $ 1,627,534 $ 0
License costs    
Research and development    
Cost of Goods and Services Sold $ 6,272,505 $ 0